Glenview Trust co Lowers Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Glenview Trust co trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,051 shares of the medical equipment provider’s stock after selling 868 shares during the quarter. Glenview Trust co’s holdings in Zimmer Biomet were worth $428,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Atria Investments Inc lifted its stake in shares of Zimmer Biomet by 60.2% during the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider’s stock worth $586,000 after purchasing an additional 2,041 shares during the last quarter. KBC Group NV lifted its stake in shares of Zimmer Biomet by 64.0% during the 3rd quarter. KBC Group NV now owns 25,287 shares of the medical equipment provider’s stock worth $2,730,000 after purchasing an additional 9,864 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Zimmer Biomet by 7.4% during the 3rd quarter. CIBC Asset Management Inc now owns 29,718 shares of the medical equipment provider’s stock worth $3,208,000 after purchasing an additional 2,039 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Zimmer Biomet by 6.8% during the 3rd quarter. Empowered Funds LLC now owns 4,135 shares of the medical equipment provider’s stock worth $446,000 after purchasing an additional 265 shares during the last quarter. Finally, Natixis Advisors LLC lifted its stake in shares of Zimmer Biomet by 24.7% during the 3rd quarter. Natixis Advisors LLC now owns 63,651 shares of the medical equipment provider’s stock worth $6,871,000 after purchasing an additional 12,602 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James reduced their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Stifel Nicolaus upped their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays reduced their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Up 1.7 %

Shares of ZBH opened at $111.85 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $22.26 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 1.95 and a beta of 1.04. The stock’s 50-day moving average price is $105.99 and its 200-day moving average price is $106.90.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business earned $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.